舒肝解郁胶囊治疗精神分裂症后抑郁患者的疗效与安全性分析  

Analysis of efficacy and safety of Shugan Jieyu capsules in treatment of post schizophrenia depression

作　　者：蔺振林 王都[1] LIN Zhenlin;WANG Du(Tianshui Third People＇s Hospital,Tianshui Gansu 741000,China)

机构地区：[1]天水市第三人民医院,甘肃天水741000

出　　处：《中国民康医学》2018年第16期60-61,共2页Medical Journal of Chinese People’s Health

摘　　要：目的:观察舒肝解郁胶囊治疗精神分裂症后抑郁患者的临床疗效及其安全性。方法:选择精神分裂症后抑郁患者158例作为本次观察对象,将入选患者随机编号并以交替方式分为对照组和研究组,每组79例。对照组使用艾司西酞普兰治疗,研究组在对照组用药基础上加用舒肝解郁胶囊治疗,两组均连续治疗6周。比较两组临床疗效及药物不良反应发生情况。结果:研究组临床治疗总有效率(97.47%)明显高于对照组(86.08%),差异有统计学意义(P<0.05),研究组不良反应发生率(5.06%)明显低于对照组(16.46%),差异有统计学意义(P<0.05)。结论:在艾司西酞普兰治疗基础上,采用舒肝解郁胶囊治疗精神分裂症后抑郁患者的疗效及安全性优于单纯艾司西酞普兰治疗。Objective： To observe efficacy and safety of Shugan Jieyu capsules in treatment of post schizophrenia depression.Methods： 158 cases of post schizophrenic depression were selected as the subjects. They were divided into control group and research group according to the random number table method,79 cases in each group. The control group used Escitalopram treatment,while the study group was treated with Shugan Jieyu capsules combined with Escitalopram. The treatment lasted for 6 consecutive weeks. The efficacies and adverse drug reactions of the two groups were compared. Results： The total effective rate of the study group（97.47%） was significantly higher than that of the control group（86.08%）,and the difference was statistically significant（P〈0.05）. The incidence of adverse reactions the study group（5.06%） was significantly lower than that of the control group（16.46%）,and the difference was statistically significant（P〈0.05）. Conclusions： Shuganjieyu capsules combined with Escitalopram in the treatment of post schizophrenia depression is more effective and safer than single Escitalopram.

关 键 词：舒肝解郁胶囊 精神分裂症后抑郁 安全性 

分 类 号：R749.3[医药卫生—神经病学与精神病学]